GSK agrees to acquire myeloma therapy. GSK stock costs EUR 20.83

GSK stock costs EUR 20.83 in weekend trading on October 4, 2026 versus its EUR 20.83 Xetra close. GSK agreed to acquire a myeloma therapy program.

GSK agreed on September 15, 2026, to acquire a trispecific T-cell engager from Chimagen Biosciences for multiple myeloma, according to a GSK release. The agreement has a potential total value of up to USD 750 million. At 6:15 p.m. CEST on October 4, 2026, GSK stock was EUR 20.83 in weekend trading at Lang & Schwarz, unchanged from the EUR 20.83 close at Lang & Schwarz on October 2.

Weekend trading

Lang & Schwarz listed a bid of EUR 20.71 and an ask of EUR 20.95 alongside the EUR 20.83 weekend-trading price. The further course of weekend trading at Lang & Schwarz until 7:00 p.m. CET/CEST is shown by the continuously updated real-time quote of GSK stock.

Myeloma program

GSK said the acquired program is designed to bind to T cells while targeting two tumor-associated antigens. The company plans to develop and commercialize the asset, with the program expected to enter Phase I trials in 2027. Chimagen is eligible for success-based development and commercial milestone payments under the agreement, the GSK release said.

Next Xetra session

The next Xetra session is scheduled for October 5, 2026. The October 2 close at Lang & Schwarz remains the reference level for the October 4 weekend-trading indication.